HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1

被引:15
|
作者
Quesnel-Vallieres, Mathieu [1 ,4 ]
Lemay, Mireille [2 ,5 ]
Lapointe, Normand [2 ,5 ]
Martin, Steven R. [3 ,5 ]
Soudeyns, Hugo [1 ,4 ,5 ]
机构
[1] CHU St Justine, Ctr Rech, Unite Immunopathol Virale, Montreal, PQ H3T 1C5, Canada
[2] CHU St Justine, Ctr Rech, Ctr Maternal & Infantile SIDA, Montreal, PQ H3T 1C5, Canada
[3] CHU St Justine, Ctr Rech, Serv Gastroenterol & Nutr, Montreal, PQ H3T 1C5, Canada
[4] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada
[5] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada
关键词
Hepatitis C virus; Coinfection; Pediatrics; Mother-to-child transmission; Interferon; Ribavirin;
D O I
10.1016/j.jcv.2008.06.019
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Two children who acquired hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infection by mother-to-child transmission were monitored during interferon alfa-2b and ribavirin treatment. In Patient C1, CD4(+) T cell counts were within normal range and HIV-1 viral load was undetectable. HCV viral load declined slightly following treatment initiation while novel variants rapidly emerged, indicative of quasispecies diversification. In Patient C2, CD4(+) T cell counts were low and HIV-1 replication was not fully controlled by antiretroviral therapy. HCV viral load rose during treatment and a striking conservation of the variant spectrum was observed. In both cases, there was no decline in quasispecies complexity following treatment initiation and sustained virological response was not achieved. These results suggest that reduction in quasispecies complexity, which is observed in adult responders following interferon treatment, may be mechanistically unrelated with evolution of the variant profile and/or selective pressure exerted on HCV. (C) 2008 Elsevier B.V. All rights reserved
引用
收藏
页码:236 / 240
页数:5
相关论文
共 50 条
  • [41] No Effect of Pegylated Interferon-α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients
    Strouvelle, Victoria P.
    Braun, Dominique L.
    Vongrad, Valentina
    Scherrer, Alexandra U.
    Kok, Yik Lim
    Kouyos, Roger D.
    Stockle, Marcel
    Rauch, Andri
    Darling, Katharine
    Hoffmann, Matthias
    Metzner, Karin J.
    Guenthard, Huldrych F.
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (12): : 1883 - 1888
  • [42] Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin
    Pavan, M. H. P.
    Velho, P. E. N. F.
    Vigani, A. G.
    Goncalves, F. L.
    Aoki, F. H.
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (03): : 383 - 384
  • [43] Clinical depression in chronic hepatitis c (HCV) patients receiving two different interferon alfa-2b ribavirin combination (Rebetron) regimens.
    Wong, PWK
    Lawitz, EJ
    Cantu, NS
    Kadakia, SC
    HEPATOLOGY, 2000, 32 (04) : 561A - 561A
  • [44] Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study
    Dieterich, Douglas
    Rockstroh, Juergen Kurt
    Orkin, Chloe
    Gutierrez, Felix
    Klein, Marina B.
    Reynes, Jacques
    Shukla, Umesh
    Jenkins, Alan
    Lenz, Oliver
    Ouwerkerk-Mahadevan, Sivi
    Peeters, Monika
    De La Rosa, Guy
    Tambuyzer, Lotke
    Jessner, Wolfgang
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (11) : 1579 - 1587
  • [45] Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
    Mira, J. A.
    Neukam, K.
    Lopez-Cortes, L. F.
    Rivero-Juarez, A.
    Tellez, F.
    Giron-Gonzalez, J. A.
    de los Santos-Gil, I.
    Ojeda-Burgos, G.
    Merino, D.
    Rios-Villegas, M. J.
    Collado, A.
    Torres-Cornejo, A.
    Macias, J.
    Rivero, A.
    Perez-Perez, M.
    Pineda, J. A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (09) : 1879 - 1884
  • [46] Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial
    Rodriguez-Torres, Maribel
    Slim, Jihad
    Bhatti, Laveeza
    Sterling, Richard
    Sulkowski, Mark
    Hassanein, Tarek
    Serrao, Rosario
    Sola, Ricard
    Bertasso, Anne
    Passe, Sharon
    Stancic, Saray
    HIV CLINICAL TRIALS, 2012, 13 (03): : 142 - 152
  • [47] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    Manns, MP
    McHutchison, JG
    Gordon, SC
    Rustgi, VK
    Shiffman, M
    Reindollar, R
    Goodman, ZD
    Koury, K
    Ling, MH
    Albrecht, JK
    LANCET, 2001, 358 (9286): : 958 - 965
  • [48] Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children
    Pawlowska, Malgorzata
    Pilarczyk, Malgorzata
    Halota, Waldemar
    MEDICAL SCIENCE MONITOR, 2010, 16 (12): : CR616 - CR621
  • [49] VIROLOGICAL RESPONSE TO TREATMENT WITH PEGYLATED INTERFERON ALFA-2B AND RIBAVIRIN CHRONIC HEPATITIS C IN CHILDREN
    Pawlowska, Malgorzata
    Pilarczyk, Malgorzata
    Halota, Waldemar
    Jendryczka, Ewa
    HEPATOLOGY, 2008, 48 (04) : 855A - 856A
  • [50] Growth factors versus dose reduction for pegylated interferon alfa-2b and ribavirin associated neutropenia and anemia in HIV/HCV co-infected patients
    Kadam, Jaydeep S.
    Jones, Kristina
    Peterson, Ray
    Dove, Loren
    Pearce, Daniel
    Hassanein, Tarek
    Doonquah, Leeleka
    Glesby, Marshal
    Heller, Larry
    Aboulafia, David
    Rodriguez, Jorge
    Bonilla, Hector
    Galpin, Jeff
    Aberg, Judy
    Johnston, Barbara
    Liu, Ray
    Jacobson, Ira M.
    Talal, Andrew H.
    GASTROENTEROLOGY, 2006, 130 (04) : A838 - A839